Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Advisory committee will discuss tools for Alzheimer’s diagnosis

Executive Summary

The Peripheral and Central Nervous System Drugs Advisory Committee will meet Oct. 23 to discuss the development of radionuclide imaging for amyloid detection to assist in diagnosing Alzheimer's disease. The buildup of amyloid plaque may be a key characteristic of the disease, but so far no company has successfully developed an anti-amyloid therapy (1"The Pink Sheet," Aug. 4, 2008, p. 15). Firms unveiled data on their respective agents at the International Conference on Alzheimer's Disease. Phase II data from Lilly's anti-amyloid beta monoclonal antibody LY2062430 showed no change in patients' cognitive score or the amount of plaque in the brain, and a Phase II study of Wyeth/Elan's bapineuzumab, a monoclonal antibody thought to induce an immune response to clear beta amyloid plaque buildup in the brain, failed to meet its primary efficacy endpoints

You may also be interested in...



Anti-Amyloid Still All The RAGE At Alzheimer’s Disease Conference

A little more than a week after an article published in The Lancet raised questions about the assumption that removing amyloid plaque is key to modifying Alzheimer's disease - an assumption upon which most drug makers are pinning their hopes - Wyeth, Lilly and Pfizer unveiled data on their respective agents at the International Conference on Alzheimer's Disease in Chicago

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050058

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel